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Dialysate iron therapy: Infusion of soluble ferric pyrophos- with prematurity and low birth weight during pregnancy,
phate via the dialysate during hemodialysis. defects in cognitive and psychomotor development dur-
Background. Soluble iron salts are toxic for parenteral ad- ing childhood, and impaired work capacity in adulthoodministration because free iron catalyzes free radical generation.
[3–8]. Oral iron supplementation programs have failedPyrophosphate strongly complexes iron and enhances iron
primarily because of noncompliance in addition to gas-transport between transferrin, ferritin, and tissues. Hemodialy-
sis patients need iron to replenish ongoing losses. We evaluated trointestinal adverse effects [9]. As an adjunct or al-
the short-term safety and efficacy of infusing soluble ferric ternative to the oral route, iron has been administered
pyrophosphate by dialysate. parenterally for more than 100 years [10]. Soluble ironMethods. Maintenance hemodialysis patients receiving ery-
compounds are considered too toxic for parenteral ad-thropoietin were stabilized on regular doses of intravenous
ministration, as ionization of soluble iron salts liberates(i.v.) iron dextran after oral iron supplements were discon-
tinued. During the treatment phase, 10 patients received ferric free iron, which catalyzes free radical formation and lipid
pyrophosphate via hemodialysis as monthly dialysate iron con- peroxidation [11, 12]. The colloidal iron compounds used
centrations were progressively increased from 2, 4, 8, to 12
for parenteral administration such as iron dextran, sac-mg/dl and were then sustained for two additional months at 12
charate, or gluconate are also associated with seriousmg/dl (dialysate iron group); 11 control patients were continued
on i.v. iron dextran (i.v. iron group). side-effects, including hypotension and anaphylactoid re-
Results. Hemoglobin, serum iron parameters, and the eryth- actions [13]. The toxicity of these compounds may be
ropoietin dose did not change significantly from month 0 to secondary to liberation of free iron caused by chemical
month 6, both within and between the two groups. The weekly
interactions in plasma [13] or circulating antidextran an-dose of i.v. iron (mean 6 sd) needed to maintain iron balance
tibodies in patients administered repeated doses of ironduring month 6 was 56 6 37 mg in the i.v. iron group compared
with 10 6 23 mg in the dialysate iron group (P 5 0.001). dextran [14]. Ferric iron is strongly complexed by pyro-
Intravenous iron was required by all 11 patients in the i.v. iron phosphate; the log of stability or formation constant
group compared with only 2 of the 10 patients receiving 12 mg/dl (Kstab) is 22.2 [15]. Pyrophosphate is known to trigger
dialysate iron. The incidence of adverse effects was similar in
iron removal from transferrin, enhance iron transferboth groups.
from transferrin to ferritin, and promote iron exchangeConclusions. Slow infusion of soluble iron pyrophosphate
between transferrin molecules [16–19]. These propertiesby hemodialysis may be a safe and effective alternative to the
i.v. administration of colloidal iron dextran in maintenance suggest that ferric pyrophosphate may be suitable for
hemodialysis patients. parenteral administration. Furthermore, ferric pyro-
phosphate (molecular weight of 745.2) is soluble in water
when the granules have been prepared by chemical reac-
Iron deficiency is the most common nutritional prob- tion with citric acid and sodium hydroxide.
lem worldwide, causing iron-deficiency anemia in 500 to A majority of maintenance hemodialysis patients
600 million people [1, 2]. Iron deficiency is associated treated with erythropoietin become iron deficient and
need i.v. iron supplementation to maintain optimal iron
balance [20]. In hemodialysis patients, small water-solu-Key words: dialysis, iron supplementation, renal toxicity, colloidal iron
dextran, erythropoietin, anemia. ble molecules can be directly infused into the circulation
by their addition to the dialysate solution [21]. We haveReceived for publication August 25, 1998
previously demonstrated that ferric pyrophosphate isand in revised form November 24, 1998
Accepted for publication December 30, 1998 transported from the dialysate to the blood compartment
during simulated, in vitro hemodialysis (A. Gupta, un- 1999 by the International Society of Nephrology
1891
Gupta et al: Dialysate iron therapy1892
published data). The goal of this study was to determine ferritin of more than 100 mg/liter. In all patients, overt
iron deficiency (TSAT less than 20%) was treated withwhether infusion of soluble ferric pyrophosphate by dial-
ysis (dialysate iron therapy) is safe and could obviate the 100 to 200 mg of iron dextran i.v. with each hemodialysis
session, up to a total dose of 400 to 1000 mg at theneed for oral and intravenous (i.v.) iron in maintenance
hemodialysis patients. discretion of the principal investigator (A.G.). The serum
iron parameters in the last two weeks of the pretreatment
phase were used for comparison with the parameters in
METHODS
the treatment phase. During the treatment phase, a co-
Study design hort of patients was assigned to receive iron pyrophos-
phate in an escalating dose via the dialysate (dialysateInformed consent was obtained from 24 patients with
end-stage renal disease receiving maintenance hemodial- iron group) during every hemodialysis session for a total
of 24 weeks, whereas a control group continued to re-ysis for at least three months. The experimental therapy
of ferric pyrophosphate administration by hemodialysis ceive i.v. iron alone (i.v. iron group). If TSAT exceeded
50%, maintenance i.v. and/or dialysate iron supplemen-was compared with the recommended practice of mainte-
nance i.v. iron dextran treatment [20] in this open-label, tation were discontinued.
During the pretreatment phase, one patient died andsingle-center clinical study. The study was approved un-
der an Investigational New Drug Application by the one patient was transferred to another dialysis facility.
During the treatment phase, one patient from the dialy-United States Food and Drug Administration and by
the Human Rights Committee at Henry Ford Hospital sate iron group withdrew after only one dialysis session
because of lack of interest. Thus, data are reported on(Detroit, MI, USA).
The inclusion criteria for the study were as follows: the 21 patients who completed the study.
male and female patients 18 years of age or older under-
Hemodialysis with solutions containinggoing hemodialysis three times a week and receiving
ferric pyrophosphateerythropoietin for the treatment of anemia, transferrin
saturation (TSAT) between 18 and 25% and serum ferri- Ferric pyrophosphate complexed with sodium citrate
is soluble in aqueous solutions (ferric pyrophosphatetin level between 100 and 200 mg/liter, and a need for
parenteral iron supplementation within a three-month soluble; Mallinckrodt Inc., St. Louis, MO, USA) [22].
Soluble ferric pyrophosphate was dissolved in purifiedperiod prior to enrollment. Patients were excluded if
they maintained adequate iron balance (TSAT more water, and this solution was added to a freshly prepared
bicarbonate concentrate solution. Dialysate solutionsthan 25% and serum ferritin more than 200 mg/liter)
without parenteral iron supplementation or had severe containing the desired concentration of soluble ferric
pyrophosphate were generated by the addition of aniron deficiency (TSAT less than 15% and/or serum ferri-
tin less than 50 mg/liter), had a history of clinically sig- appropriately higher concentration of the compound to
the bicarbonate concentrate. A stable and clear dialysatenificant allergic reaction to iron, had a history of drug
or alcohol abuse within six months prior to enrollment, solution containing up to 71 mg/dl iron as ferric pyrophos-
phate could be generated using this method. Bicarbonatehad a history of hepatitis B or HIV infection, or were
child-bearing females not willing to use effective birth concentrate solutions were used within 24 hours of prep-
aration to avoid bacterial growth. Based on previous incontrol measures.
The study was performed in two phases, a pretreat- vitro hemodialysis studies using dialysate iron concentra-
tions between 2 and 70 mg/dl (A. Gupta, unpublishedment (month 0) phase of four weeks, followed by a
treatment phase (month 1 to 6) of 24 weeks. Predialysis data) and taking patients’ safety into consideration, in
our study, an initial dialysate iron concentration of 2hemoglobin, hematocrit, serum iron, total iron-binding
capacity (TIBC), and ferritin were measured every week mg/dl was increased every four weeks to 4, 8, and then
to a maximum of 12 mg/dl, which was then sustained forthroughout the study. Erythropoietin was administered
intravenously up to three times per week during hemodi- two additional months. All patients were dialyzed using
polysulfone membrane filters (F-80t or F-8t; Freseniusalysis, and the dose was adjusted every four weeks in
order to maintain hemoglobin levels between 10 and 12 USA, Walnut Creek, CA, USA), and the filters were
reused after heat sterilization. The hemodialysis-relatedg/dl. Starting in month 0 and during the seven-month
study period, patients were instructed not to take any parameters (mean 6 se) were as follows: dialysate flow
rate, 800 ml/min; blood flow rate, 465.1 6 14.43 ml/min;oral iron supplements. Throughout the study, all patients
were eligible to receive variable maintenance doses (0, dialysis time, 217.5 6 8.1 min; and KT/V, 1.53 6 0.13.
25, 50, or 100 mg) of supplemental i.v. iron dextran
Efficacy parameters(INFeDt; Schein Pharmaceutical, Inc., Florham Park,
NJ, USA) once a week during hemodialysis in order to Hemoglobin and hematocrit were measured weekly
by a colorimetric method, and the mean corpuscularmaintain a predialysis TSAT of more than 20% and
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Table 1. Characteristics of patients included in the final analysishemoglobin content of reticulocytes (reticulocyte hemo-
globin) was measured at the end of each month using a Characteristic Dialysate iron i.v. iron
flow cytometry method (H-3; Bayer Diagnostics, Tarry- N 10 11
town, NY, USA). Testing for reticulocyte hemoglobin Gender (male)a 6 (60%) 7 (64%)
Age (years)b 53.5614.3 (32–82) 58.1 61.5 (32–76)was not available during months 0 and 1. Serum iron,
Race (African American)a 9 (90%) 11 (100%)TIBC, and ferritin were measured weekly. Serum iron Hypertensiona 10 (100%) 11 (100%)
and TIBC were analyzed by a colorimetric method (Hi- Diabetes mellitusa 6 (60%) 7 (64%)
tachi 747; Boehringer Mannheim Corp., Indianapolis, a Indicates patients with the characteristic; number in parentheses indicates
percent of patients in the groupIN, USA). Ferritin was analyzed by a chemiluminescent
b Plus-minus values are means 6 sd, age range is shown in parenthesesimmunoassay method (ACCESS; Beckman Instruments,
Fullerton, CA, USA) until the end of month 4. The
heterogeneous competitive magnetic separation assay
(HCMSA) using Immuno-1 (Bayer Diagnostics) was comitant disease states of the patients are shown in Table
used for the determination of ferritin for the remaining 1. The predominance of African Americans was consis-
samples of the study. The two methods give similar val- tent with the demographics of our dialysis population.
ues when compared using the “College of American The efficacy parameters are shown in Table 2, whereas
Pathologists” (CAP) surveys (Dr. James Zazra, Lifechem the safety parameters are summarized in Table 3. None
Laboratories Inc., Rockleigh, NJ, USA, personal com- of these variables were statistically different between the
munication). TSAT was calculated as follows: two groups during month 0. Furthermore, there were
no significant differences in hemodialysis prescription orTSAT (%) 5 [serum iron (mg/dl)/TIBC (mg/dl)] 3 100
dialysis adequacy between the two groups in the baseline
Safety parameters or the treatment phase (data not shown).
Nutritional status was monitored by recording body
Efficacy parametersweight at every dialysis session and by monthly serum
Whole blood hemoglobin was maintained at a stablealbumin, cholesterol, and triglyceride measurements.
target level in both the groups, without any significantBecause there is a theoretical risk of ferric pyrophos-
difference in between the groups (Table 2 and Fig. 1A).phate causing hyperphosphatemia and chelation of se-
rum calcium leading to hypocalcemia, serum calcium and There was no significant change in erythropoietin dose
phosphorus were monitored monthly. Serum ferritin was throughout the study in either group and no significant
measured weekly to detect iron overload, defined as difference between the two groups (Table 2 and Fig.
ferritin greater than 800 mg/liter. Patients were closely 1B). The dose of erythropoietin was increased from 1000
monitored to detect signs and symptoms of iron toxicity to 4000 units per treatment in the final month for a
(malaise, headache, back pain, flushing, myalgia, arthral- patient in the dialysate iron group, when the hemoglobin
gia, vomiting, diarrhea, urticaria, hypotension, respira- declined following an arterial bypass procedure. This led
tory distress, anaphylactoid reactions, and lymphadenop- to an abrupt increase in the mean erythropoietin dose
athy). for the dialysate iron group in the final month of the
study.Statistical analysis
Patients in both groups were prescribed 0 to 200 mg
For each study variable, monthly averages and changes i.v. iron per dialysis session, up to a maximum total dose
from pretreatment (month 0) to the final observation of 400 mg per week. Iron balance, as determined by
period (month 6) were compared between the two TSAT and ferritin, was maintained in both groups
groups by t-test or Wilcoxon rank sum test. The changes throughout the study, with no significant difference in
from pretreatment to month 6 were also tested within TSAT (Fig. 2A) or ferritin (Fig. 2B) between the two
each group by paired t-test or Wilcoxon signed rank groups (Table 2). Reticulocyte hemoglobin, a marker of
test. Analysis was performed using the SAS procedures iron deficiency, was 28.4 6 2.9 pg in the dialysate iron
TTEST, MEANS, UNIVARIATE and NPAR1WAY group versus 27.0 6 3.5 pg in the i.v. iron group at month
[23]. Sample size was based on the anticipation that a
2 (P 5 0.32) and did not change significantly between50% decrease in maintenance iron requirements could
the two groups during the course of the treatment phasebe detected. All results are reported as mean 6 sd unless
of the study (Table 2). The TIBC was significantly higherotherwise stated, with a P of less than 0.05 considered
in the dialysate iron group compared with the i.v. ironstatistically significant.
group in month 6 (P , 0.05), despite no significant differ-
ences in iron parameters or the nutritional status of the
RESULTS two groups.
During month 0, the weekly dose of i.v. iron dextranFrom November 1996 to July 1997, a total of 21 hemo-
dialysis patients were followed. Demographic and con- in the dialysate iron group was 69 6 28 mg compared with
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Table 2. Summary of efficacy parameters: A comparison of month 6 with pre-treatment (month 0)
Pre-treatment Month 6
Parameter Dialysate iron i.v. iron Dialysate iron i.v. iron
Hemoglobin g/dl 10.660.8 10.1 61.1 10.161.1 10.1 61.4
Hematocrit % 33.462.4 32.6 63.7 32.063.9 33.0 64.2
Retic. hemoglobin pg not done not done 28.8 62.0 28.3 63.0
Serum iron lg/dl 54620 53 622 54614 50 620
TIBC lg/dl 222644 193 648 235657a 180642
TSAT % 2567 27 69 2467 26 65
Ferritin lg/liter 210689 213 653 1556121 261 6212
Erythropoietin dose units/dialysis session 399062370 5647 62519 441862299 5392 62640
i.v. iron dextran dose mg/week 69628 60 647 10 623ab 56637
Plus-minus values are mean 6 sd. Abbreviations are: Retic. hemoglobin, reticulocyte hemoglobin; TIBC, total iron binding capacity; TSAT, transferrin saturation.
a P , 0.05 when compared to i.v. iron group at month 6
b P , 0.05 when compared to pre-treatment (month 0)
Table 3. Summary of safety parameters: A comparison of month 6 to pre-treatment
Pre-treatment Month 6
Parameter Dialysate iron i.v. iron Dialysate iron i.v. iron
Albumin g/dl 3.860.4 3.860.4 3.8 60.3 3.760.5
Cholesterol mg/dl 161620 153633 160 625 136626a
Triglycerides mg/dl 2096140 127651 166 679 131649
Dry weight kg 83.0617.4 73.3627.3 78.4 619.5 69.5622.6
Serum calcium mg/dl 9.560.9 9.461.0 9.1 60.7 8.960.7
Serum phosphorus mg/dl 5.561.5 5.461.4 5.4 60.4 5.361.9
Episodes of hypotension during hemodialysis sessions 1.4 61.9 1.761.9 2.3 62.7 3.062.5
Plus-minus values are mean 6 sd.
a P , 0.05 when compared to i.v. iron group pretreatment
60 6 47 mg in the control group. Despite no significant trointestinal blood loss in one of the i.v. iron group pa-
tients. Two patients in the dialysate iron group requireddifferences in hemoglobin, TSAT, ferritin, and erythro-
poietin dose between the two groups, the requirements blood transfusions, one following coronary artery bypass
surgery and the other following the amputation of afor i.v. iron dextran were significantly reduced during
the treatment phase in the dialysate iron group (Fig. 1C). lower extremity. None of the patients exhibited evidence
of iron overload on clinical or laboratory testing. Postdi-The decrease in i.v. iron requirements in the dialysate
iron group was accompanied by a concentration-depen- alysis TSAT was monitored considering the potential
toxicity of free plasma iron if the binding capacity ofdent transfer of iron from dialysate to the blood compart-
ment, as demonstrated by an increase in postdialysis transferrin was exceeded. In 6 of the 10 patients in the
dialysate iron group, there were 12 instances when theTSAT from 31.7 6 6.8% on 2 mg/dl to 54.7 6 9.9% on
8 mg/dl and 71.8 6 13.4% on 12 mg/dl iron concentration postdialysis TSAT exceeded 90%, with no associated
signs or symptoms of iron toxicity. On three occasions(Fig. 3A). The increment in TSAT postdialysis remained
constant when dialysate iron concentration was main- in three different patients, the TSAT immediately postdi-
alysis ranged from 100 to 109%. None of these patientstained at 12 mg/dl for three months. Although we had
not planned to routinely monitor the decline in serum exhibited any signs or symptoms of iron toxicity during
these occurrences. The nutritional parameters were un-iron parameters following dialysis, in one of these pa-
tients, a rapid decline in the TSAT and serum iron con- changed for the duration of the study. Serum calcium
and phosphorus were not significantly altered when com-centration occurred over one hour, following the end of
a hemodialysis session (Fig. 3B). paring month 0 to month 6. Predialysis and postdialysis
blood pressures were not significantly different between
Safety parameters the two groups at any time during the study (data not
shown). Hypotension, as defined by systolic blood pres-There was no evidence of pulmonary or tracheobron-
chial toxicity by history or physical examination at the sure of less than 100 mm Hg or diastolic blood pressure
less than 60 mm Hg, occurred with equal frequency inend of the study. Hypersensitivity reactions were not
encountered in either group. Overt anemia requiring the two groups (Table 3).
Febrile reactions during hemodialysis secondary to ex-blood transfusions developed because of excessive gas-
cessive bacterial content of the dialysate were not ob-
served in either group, and there was no evidence for
bacterial overgrowth in iron-containing bicarbonate con-
centrates. Iron-containing dialysis solutions did not have
any adverse effect on dialyzer reuse or hemodialysis
equipment, including the sensors and dialysis tubing.
DISCUSSION
Soluble iron salts have hitherto been considered too
toxic for parenteral administration because the free iron
catalyzes formation of oxygen free radicals. We have
demonstrated that soluble ferric pyrophosphate can be
infused directly into the circulation by dialysis without
any apparent toxicity. No short-term adverse effects
were noted, even on occasions when the postdialysis
TSAT ranged between 90 and 108% while patients were
dialyzed against a dialysate iron concentration of 12
mg/dl. This may be related to the high affinity of iron
for pyrophosphate that is of the same order of magnitude
as the affinity of iron for transferrin. Therefore, ferric
pyrophosphate is a stable molecule that does not ionize
readily (pKA 22.2), resulting in negligible release of free
iron, even when the binding capacity of transferrin is
exceeded. Studies with another metal pyrophosphate
complex, stannous pyrophosphate, have reported imme-
diate toxic effects, presumably from binding of pyrophos-
phate moiety to calcium in the blood [24]. Hypocalcemia
was not observed in patients receiving ferric pyrophos-
phate, as the ferric ion is more strongly complexed by
pyrophosphate than is the stannous ion (pKi approxi-
mately 5) or the calcium ion (pKi approximately 5 to 8)
[25, 26].
The colloidal iron compounds are processed in the
reticuloendothelial system before iron is released into
the circulation. On the other hand, pyrophosphate moi-
ety in circulating ferric pyrophosphate is directly able to
trigger iron transfer to transferrin, between transferrin
molecules and between transferrin and ferritin [16–19]
without the need for prior processing by the reticuloen-
dothelial system. In this respect, metabolism of ferric
pyrophosphate resembles physiological processing of
iron delivered into the circulation after absorption by
the gut. The differences in metabolism of soluble and
colloidal iron compounds may be responsible for the
divergent trends in serum ferritin concentration during
the course of the study (Fig. 2B). With the maximum
dialysate concentration of ferric pyrophosphate tested, Fig. 1. Whole blood hemoglobin (A) and erythropoietin dose per he-
modialysis session (B) three times a week remained stable during thethe TSAT increased from a predialysis level of 23.6 6
course of the study (mean 6 SE). Symbols are: (d) dialysate iron group;7.1% to 74.2 6 17.2% at the end of hemodialysis and
(n) i.v. iron group. The average weekly intravenous iron dose (C) was
returned to the predialysis levels within 48 hours. This similar in the two groups during the pretreatment phase (month 0).
During the treatment phase (month 1 to 6), patients receiving dialysatedecline in TSAT following infusion of ferric pyrophos-
iron had a significantly decreased requirement for i.v. iron comparedphate is much more rapid compared with when 50 or
with the group receiving i.v. iron alone. *P , 0.05, †P , 0.003, dialysate
100 mg of i.v. iron dextran is administered (A. Besarab, iron group vs. i.v. iron group; ‡P , 0.003, pretreatment vs. month 6
within the dialysate iron group.unpublished data). The mean weekly i.v. iron require-
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Fig. 2. Predialysis serum transferrin saturation (A) and serum ferritin
(B). There was no significant difference between the two groups. Also,
there was no significant change from baseline over time within each
group. Data are means 6 se. Symbols are: (d) dialysate iron group;
(n) i.v. iron group.
ment was reduced by approximately 40 mg in the dialy-
sate iron group, suggesting that approximately 10 to 15 Fig. 3. Postdialysis serum transferrin saturation (TSAT) indicated a
mg of iron are delivered via the dialysate during each concentration-dependent increase as dialysate iron concentration was
increased from 2 to 12 mg/dl, and TSAT remained stable during thehemodialysis.
last three months when the dialysate iron concentration was maintainedIt is estimated that nearly two thirds of the mainte- at 12 mg/dl (A). In a patient, TSAT and serum iron were measured
nance hemodialysis population in the United States is over one hour, following completion of a dialysis session using 12 mg/dl
dialysate iron; a rapid decline in TSAT and serum iron was noted (B).receiving i.v. iron dextran (Amgen Inc., Thousand Oaks,
Symbols are: (d) dialysate iron group; (.) serum iron (mg/dl); (j)CA, USA), the only iron compound available for paren- transferrin saturation (%).
teral administration in the United States at this time.
Furthermore, the use of i.v. iron is expected to increase
following the recommendations by the National Kidney
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Foundation-Dialysis Outcome Quality Initiative [20]. In- side-effects and expense associated with i.v. or intramus-
cular colloidal iron compounds have limited their appli-travenous iron dextran therapy is associated with arthral-
gia–myalgia syndrome in 4.7% and serious or life-threat- cation. The safety and efficacy of slow ferric pyrophos-
phate infusion by hemodialysis suggest feasibility ofening reactions in 0.7% of patients [27]. Because acute
reactions can occur after subsequent dosing, a test dose parenteral administration of this compound to nondial-
ysis patients, although this merits further investigation.is recommended before every course of parenteral iron
therapy [27]. Furthermore, iron dextran induced loin and Water solubility and the relatively small molecular
weight of ferric pyrophosphate, compared with colloidalepigastric pain, or hypotension may interfere with the
dialysis treatment. There is also concern about potential iron compounds, suggest that it may be suitable for use
in transdermal or subcutaneous delivery systems. Theiron overload with i.v. therapy, leading to increased risk
of infection and possibly cancer [28]. Furthermore, fre- feasibility of administering ferric pyrophosphate to non-
dialysis patients by the parenteral route needs to bequent administration of i.v. iron dextran to maintenance
hemodialysis patients may be associated with increased determined by further elucidation of its ferrokinetics
and metabolism, including transfer of iron to transferrin,risk of mortality from all causes and specifically from
infections and cardiac diseases (i.v. iron dosing patterns assessment of direct uptake by the tissues, and safety
when the iron-binding capacity of transferrin is ex-and mortality; abstract; Collins et al, J Am Soc Nephrol
9:205A, 1998). ceeded.
In conclusion, we have demonstrated that iron can beThis study demonstrated that transfer of soluble ferric
pyrophosphate into the circulation by the process of he- infused into the circulation by the process of dialysis
when ferric pyrophosphate is added to the hemodialysismodialysis is effective in maintaining iron balance. Al-
though the actual amount of iron transferred by hemodi- solution. A dialysate iron concentration of 12 mg/dl was
found to be safe, and the amount of iron transferredalysis was not measured, it was sufficient to maintain an
iron balance in 8 of the 10 patients, without an additional was sufficient to maintain iron balance in a majority of
maintenance hemodialysis patients, thereby significantlyneed for oral or i.v. iron supplementation. The two pa-
tients who required additional iron had an interruption reducing the requirements for i.v. iron supplementation.
This novel method of iron administration to hemodialy-in their dialysate iron therapy because of hospitalization
and suffered excessive iron losses consequent to surgery. sis patients merits further investigation to determine its
long-term safety and efficacy.This suggests that dialysate iron therapy may be able to
maintain iron balance in the majority of hemodialysis
patients and thereby forego any adjunctive oral or i.v. ACKNOWLEDGMENTS
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